Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Assets (2020 - 2025)

Apellis Pharmaceuticals has reported Return on Assets over the past 6 years, most recently at 0.11% for Q4 2025.

  • Quarterly results put Return on Assets at 0.11% for Q4 2025, up 8.0% from a year ago — trailing twelve months through Dec 2025 was 0.11% (up 8.0% YoY), and the annual figure for FY2025 was 0.12%, up 8.0%.
  • Return on Assets for Q4 2025 was 0.11% at Apellis Pharmaceuticals, down from 0.07% in the prior quarter.
  • Over the last five years, Return on Assets for APLS hit a ceiling of 0.07% in Q3 2025 and a floor of 0.78% in Q3 2021.
  • Median Return on Assets over the past 5 years was 0.24% (2025), compared with a mean of 0.29%.
  • Biggest five-year swings in Return on Assets: soared 56bps in 2022 and later crashed -56bps in 2023.
  • Apellis Pharmaceuticals' Return on Assets stood at 0.45% in 2021, then surged by 77bps to 0.1% in 2022, then plummeted by -544bps to 0.66% in 2023, then surged by 70bps to 0.2% in 2024, then skyrocketed by 42bps to 0.11% in 2025.
  • The last three reported values for Return on Assets were 0.11% (Q4 2025), 0.07% (Q3 2025), and 0.25% (Q2 2025) per Business Quant data.